NCT06266975

Brief Summary

To study the Prevalence ,Characteristics and outcome of CKD in patiants with chronic myeloid leukemia .

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
5mo left

Started Feb 2024

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Feb 2024Nov 2026

First Submitted

Initial submission to the registry

November 3, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
19 days until next milestone

First Posted

Study publicly available on registry

February 20, 2024

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2026

Last Updated

February 20, 2024

Status Verified

February 1, 2024

Enrollment Period

2.8 years

First QC Date

November 3, 2023

Last Update Submit

February 16, 2024

Conditions

Chronic Myeloid Leukemia in Remission

Outcome Measures

Primary Outcomes (1)

  • Chronic Kidney Disease Patient in Chronic Myloied Leukemia

    Using Non Invasive or invasive Methods and correlation between lab and radiological methods to find and a relation between CML and CKD and outcome.

    basline

Interventions

Biobsy from kidneyDEVICE

using tyrosine kinase inhibitors particulary imatinib in ttt CML patients

Also known as: drug , tyrosine kinase inhibitors particulary imatinib in ttt CML patients

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all sexes , adult , not diabetic , not known CKD before diagnosed of CML

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5. Epub 2016 Nov 23.

    PMID: 27887750BACKGROUND

  • Fathallah-Shaykh SA, Flynn JT, Pierce CB, Abraham AG, Blydt-Hansen TD, Massengill SF, Moxey-Mims MM, Warady BA, Furth SL, Wong CS. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol. 2015 Apr 7;10(4):571-7. doi: 10.2215/CJN.07480714. Epub 2015 Jan 29.

    PMID: 25635034BACKGROUND

MeSH Terms

Interventions

Dosage Forms

Intervention Hierarchy (Ancestors)

Pharmaceutical PreparationsTechnology, PharmaceuticalInvestigative Techniques

Study Officials

  • Ahmed Ramadan

    Assist

    PRINCIPAL INVESTIGATOR

  • Mohamed Ramadan

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

sahar mohamed gad, third

CONTACT

01007531866sahargad22397@gmail.com

Mohamad Ramadan Abd_Elhamied, first

CONTACT

01097510010drmuhamadramadan@yahoo.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
doctor

Study Record Dates

First Submitted

November 3, 2023

First Posted

February 20, 2024

Study Start

February 1, 2024

Primary Completion (Estimated)

November 1, 2026

Study Completion (Estimated)

November 1, 2026

Last Updated

February 20, 2024

Record last verified: 2024-02